Genotypes and Haplotypes of the VEGF Gene and Survival in Locally Advanced Non-small Cell Lung Cancer Patients Treated with Chemoradiotherapy

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2010 Aug 18

PMID 20712888

Citations 15

Authors

Xiaoxiang Guan

Ming Yin

Qingyi Wei

Hui Zhao

Zhensheng Liu

Li-E Wang

Xianglin Yuan

Michael S OReilly

Ritsuko Komaki

Zhongxing Liao

Affiliations

Soon will be listed here.

Abstract

Background: Vascular endothelial growth factor (VEGF) is a major mediator of angiogenesis involving in carcinogenesis, including lung cancer. We hypothesized that VEGF polymorphisms may affect survival outcomes among locally advanced non-small cell lung cancer (LA-NSCLC) patients.

Methods: We genotyped three potentially functional VEGF variants [-460 T > C (rs833061), -634 G > C (rs2010963), and +936 C > T (rs3025039)] and estimated haplotypes in 124 Caucasian patients with LA-NSCLC treated with definitive radiotherapy. We used Kaplan-Meier log-rank tests, and Cox proportional hazard models to evaluate the association between VEGF variants and overall survival (OS).

Results: Gender, Karnofsky's performance scores (KPS) and clinical stage seemed to influence the OS. The variant C genotypes were independently associated with significantly improved OS (CT+CC vs. TT: adjusted hazard ratio [HR] = 0.58; 95% confidence interval [CI] = 0.37-0.92, P = 0.022), compared with the VEGF -460 TT genotype.

Conclusions: Our study suggests that VEGF -460 C genotypes may be associated with a better survival of LA-NSCLC patients after chemoradiotherapy. Large studies are needed to confirm our findings.

Citing Articles

Prospective Exploratory Analysis of Angiogenic Biomarkers in Peripheral Blood in Advanced NSCLC Patients Treated With Bevacizumab Plus Chemotherapy: The ANGIOMET Study.

Jantus-Lewintre E, Massuti Sureda B, Gonzalez Larriba J, Rodriguez-Abreu D, Juan O, Blasco A Front Oncol. 2021; 11:695038.

PMID: 34381717 PMC: 8350788. DOI: 10.3389/fonc.2021.695038.

Hypoxia in Lung Cancer Management: A Translational Approach.

Ancel J, Perotin J, Dewolf M, Launois C, Mulette P, Nawrocki-Raby B Cancers (Basel). 2021; 13(14).

PMID: 34298636 PMC: 8307602. DOI: 10.3390/cancers13143421.

Potentially functional variants of HBEGF and ITPR3 in GnRH signaling pathway genes predict survival of non-small cell lung cancer patients.

Wu Y, Liu Z, Tang D, Liu H, Luo S, Stinchcombe T Transl Res. 2021; 233:92-103.

PMID: 33400994 PMC: 8184605. DOI: 10.1016/j.trsl.2020.12.009.

Prognostic effect of VEGF gene variants in metastatic non-small-cell lung cancer patients.

Sullivan I, Riera P, Andres M, Altes A, Majem M, Blanco R Angiogenesis. 2019; 22(3):433-440.

PMID: 30977010 DOI: 10.1007/s10456-019-09668-y.

Potentially Functional Variants of ATG16L2 Predict Radiation Pneumonitis and Outcomes in Patients with Non-Small Cell Lung Cancer after Definitive Radiotherapy.

Wen J, Liu H, Wang L, Wang X, Gu N, Liu Z J Thorac Oncol. 2018; 13(5):660-675.

PMID: 29454863 PMC: 6124306. DOI: 10.1016/j.jtho.2018.01.028.

References

Dassoulas K, Gazouli M, Rizos S, Theodoropoulos G, Christoni Z, Nikiteas N . Common polymorphisms in the vascular endothelial growth factor gene and colorectal cancer development, prognosis, and survival. Mol Carcinog. 2008; 48(6):563-9. DOI: 10.1002/mc.20495. View

Kim J, Sohn S, Chae Y, Cho Y, Bae H, Yan G . Vascular endothelial growth factor gene polymorphisms associated with prognosis for patients with gastric cancer. Ann Oncol. 2007; 18(6):1030-6. DOI: 10.1093/annonc/mdm085. View

Yuan A, Yu C, Chen W, Lin F, Kuo S, Luh K . Correlation of total VEGF mRNA and protein expression with histologic type, tumor angiogenesis, patient survival and timing of relapse in non-small-cell lung cancer. Int J Cancer. 2000; 89(6):475-83. DOI: 10.1002/1097-0215(20001120)89:6<475::aid-ijc2>3.0.co;2-t. View

Renner W, Kotschan S, Hoffmann C, Obermayer-Pietsch B, Pilger E . A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels. J Vasc Res. 2001; 37(6):443-8. DOI: 10.1159/000054076. View

Lu H, Shu X, Cui Y, Kataoka N, Wen W, Cai Q . Association of genetic polymorphisms in the VEGF gene with breast cancer survival. Cancer Res. 2005; 65(12):5015-9. DOI: 10.1158/0008-5472.CAN-04-2786. View

Han H, Silverman J, Santucci T, Macherey R, dAmato T, Tung M . Vascular endothelial growth factor expression in stage I non-small cell lung cancer correlates with neoangiogenesis and a poor prognosis. Ann Surg Oncol. 2001; 8(1):72-9. DOI: 10.1007/s10434-001-0072-y. View

Heist R, Zhai R, Liu G, Zhou W, Lin X, Su L . VEGF polymorphisms and survival in early-stage non-small-cell lung cancer. J Clin Oncol. 2008; 26(6):856-62. DOI: 10.1200/JCO.2007.13.5947. View

Lee S, Lee S, Jeon H, Park S, Jang J, Lee G . Vascular endothelial growth factor gene polymorphisms and risk of primary lung cancer. Cancer Epidemiol Biomarkers Prev. 2005; 14(3):571-5. DOI: 10.1158/1055-9965.EPI-04-0472. View

Tzanakis N, Gazouli M, Rallis G, Giannopoulos G, Papaconstantinou I, Theodoropoulos G . Vascular endothelial growth factor polymorphisms in gastric cancer development, prognosis, and survival. J Surg Oncol. 2006; 94(7):624-30. DOI: 10.1002/jso.20619. View

10.

Stevens A, Soden J, Brenchley P, Ralph S, Ray D . Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. Cancer Res. 2003; 63(4):812-6. View

11.

Yang P, Allen M, Aubry M, Wampfler J, Marks R, Edell E . Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003. Chest. 2005; 128(1):452-62. DOI: 10.1378/chest.128.1.452. View

12.

Jin Q, Hemminki K, Enquist K, Lenner P, Grzybowska E, Klaes R . Vascular endothelial growth factor polymorphisms in relation to breast cancer development and prognosis. Clin Cancer Res. 2005; 11(10):3647-53. DOI: 10.1158/1078-0432.CCR-04-1803. View

13.

Formento J, Etienne-Grimaldi M, Francoual M, Pages G, Onesto C, Formento P . Influence of the VEGF-A 936C>T germinal polymorphism on tumoral VEGF expression in head and neck cancer. Pharmacogenomics. 2009; 10(8):1277-83. DOI: 10.2217/pgs.09.54. View

14.

Watson C, WEBB N, Bottomley M, Brenchley P . Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine. 2000; 12(8):1232-5. DOI: 10.1006/cyto.2000.0692. View

15.

Steffensen K, Waldstrom M, Brandslund I, Jakobsen A . The relationship of VEGF polymorphisms with serum VEGF levels and progression-free survival in patients with epithelial ovarian cancer. Gynecol Oncol. 2010; 117(1):109-16. DOI: 10.1016/j.ygyno.2009.11.011. View

16.

Zhai R, Liu G, Zhou W, Su L, Heist R, Lynch T . Vascular endothelial growth factor genotypes, haplotypes, gender, and the risk of non-small cell lung cancer. Clin Cancer Res. 2008; 14(2):612-7. DOI: 10.1158/1078-0432.CCR-07-1655. View

17.

Jain L, Vargo C, Danesi R, Sissung T, Price D, Venzon D . The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors. Mol Cancer Ther. 2009; 8(9):2496-508. PMC: 2751847. DOI: 10.1158/1535-7163.MCT-09-0302. View

18.

Langer C, Soria J . The role of anti-epidermal growth factor receptor and anti-vascular endothelial growth factor therapies in the treatment of non-small-cell lung cancer. Clin Lung Cancer. 2010; 11(2):82-90. DOI: 10.3816/CLC.2010.n.011. View

19.

Kim J, Chae Y, Sohn S, Cho Y, Moon J, Park J . Vascular endothelial growth factor gene polymorphisms associated with prognosis for patients with colorectal cancer. Clin Cancer Res. 2008; 14(1):62-6. DOI: 10.1158/1078-0432.CCR-07-1537. View

20.

Hefler L, Mustea A, Konsgen D, Concin N, Tanner B, Strick R . Vascular endothelial growth factor gene polymorphisms are associated with prognosis in ovarian cancer. Clin Cancer Res. 2007; 13(3):898-901. DOI: 10.1158/1078-0432.CCR-06-1008. View